21 CFR 814.106
§ 814.106 HDE amendments and resubmitted HDE's.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 814.106, § 814.106 HDE amendments and resubmitted HDE's, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/88879
- Permanent ID
ys:prov:88879@1- SHA-256
619f889eb92fbb517d5c41a1d878bcb28a6a21abc8542b2eab0d65fc02d8de50
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
An HDE or HDE supplement may be amended or resubmitted upon an applicant's own initiative, or at the request of FDA, for the same reasons and in the same manner as prescribed for PMA's in § 814.37, except that the timeframes set forth in § 814.37(c)(1) and (d) do not apply. If FDA requests an HDE applicant to submit an HDE amendment, and a written response to FDA's request is not received within 75 days of the date of the request, FDA will consider the pending HDE or HDE supplement to be withdrawn voluntarily by the applicant. Furthermore, if the HDE applicant, on its own initiative or at FDA's request, submits a major amendment as described in § 814.37(c)(1), the review period may be extended up to 75 days.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.